Align Technology, Inc. appears in FDA device records as the applicant for the Invisalign System, filed from 2820 Orchard Pkwy., San Jose, California. The September 25, 2026 clearance K262196 covers the Invisalign System under 21 CFR 872.5470, Orthodontic Plastic Bracket, Class II, with product codes PNN and NXC. The FDA database entry lists the device name as Invisalign System and the associated device name as Orthodontic Software, with a dental advisory committee. The company describes the same system as a combination of virtual modeling software, rapid manufacturing, mass customization and aligners made from a patented material. [1][2][4]

Documented FDA filings and predicates

K262196 was dated and received June 29, 2026, and cleared September 25, 2026 as substantially equivalent under a traditional review with a summary. The FDA clearance letter states the subject device and the cleared predicate Invisalign System (K252380) share the same intended use, the same indications for use, similar principles of operation and similar technological characteristics. K252380 itself was dated and received July 30, 2025 and cleared August 29, 2025, also under 21 CFR 872.5470 with product codes NXC and PNN. [1][2][9]

An earlier clearance, K241412, was dated and received May 17, 2024 and cleared June 18, 2024, again under 21 CFR 872.5470 with product codes NXC and PNN. Its primary predicate was K232233, an earlier Invisalign System submission. The stated indication covers orthodontic treatment of malocclusion in patients with primary, mixed or permanent dentition. [8]

Product composition as described by the company

Align Technology's own pages describe the Invisalign System as used for straightening teeth with a series of custom-made aligners for each patient, built from proprietary virtual modeling software, rapid manufacturing processes, mass customization and aligners with patented material. The company states the system addresses clinical situations from simple to complex. The same pages describe iTero intraoral scanners as a separate product line for dental practices. [4][6][7]

Company-published figures on the Align Technology site list annualized net revenues above $4.1 billion, approximately 24.2 million Invisalign patients including about 7.3 million teens and kids, 2,412 active patents and more than 20,000 global employees. These are company-reported metrics, not FDA findings. [7]

Filing scope and regulatory pathway

The MedtechLedger collection contains one linked 510(k) record, K262196, with a Substantially Equivalent decision. The record sample contains that same entry with one SESE decision. These counts describe the linked collection as of November 20, 2026, rather than the company’s total filings or sales. This sample contains no recall records, which does not establish an absence of recalls elsewhere. [1]

The FDA database entry for K262196 lists the applicant address in San Jose, California, and a dental advisory committee with a Class II designation. The clearance letter identifies the regulation as 21 CFR 872.5470, Orthodontic Plastic Bracket, and the review as a traditional 510(k) with a summary and no third-party review. [1][2]

Identity and attribution

Align Technology, Inc. is the applicant named across the cited FDA letters, each addressed to a regulatory affairs specialist at the San Jose address. The company's own site identifies Align Technology as a global medical device company and names Joe Hogan as President and CEO. The site also states the Invisalign System is available across the world and directs readers to search for a local Invisalign doctor. [2][7][8][9]

Company pages describe the Invisalign System as backed by over two decades of innovation and as having helped bring smiles to more than 23 million people in one version and more than 24 million in another; the site's key metrics page gives approximately 24.2 million patients. These are company statements, and the differing figures are reported as published rather than reconciled. [4][6][7]